NeuroMetrix (NASDAQ:NURO) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of NeuroMetrix (NASDAQ:NURO) in a report issued on Tuesday morning. The firm issued a sell rating on the medical device company’s stock.

NeuroMetrix Price Performance

NASDAQ NURO traded down $0.12 on Tuesday, hitting $3.67. 1,774 shares of the company’s stock were exchanged, compared to its average volume of 25,845. The firm has a market cap of $7.49 million, a price-to-earnings ratio of -0.83 and a beta of 2.29. The firm’s 50-day moving average price is $4.02 and its two-hundred day moving average price is $3.86. NeuroMetrix has a fifty-two week low of $2.66 and a fifty-two week high of $4.73.

NeuroMetrix (NASDAQ:NURO) last announced its quarterly earnings data on Tuesday, November 5th. The medical device company reported ($0.75) EPS for the quarter. The company had revenue of $0.59 million during the quarter. NeuroMetrix had a negative net margin of 203.71% and a negative return on equity of 42.56%. During the same period last year, the business earned ($1.66) EPS.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.